Skip Navigation

Latin America & Caribbean

News

  • Print
  • Comment
  • | Share

Drug licences all for the poor, says Thai minister

Source: Science

8 June 2007 | 中文 | EN

Thailand will licence five drugs at a time

Thailand will licence five drugs at a time

Abinoam Jr

The Thai minister of public health, Mongkol Na Songkhla, says the government's decision to issue compulsory licences on patented drugs was aimed solely at helping poor people, and that the country has borne "unfair" criticism.

In an interview in the journal Science (8 June), Mongkol explains that Thailand has limited itself to only issuing compulsory licences for five drugs at a time. This will minimise interference into research and development, innovation and investment, and still address the needs of the country's poor, he says.

He concedes that compulsory licensing was in part a tactic to encourage negotiation with drug companies. "They never wanted to sit down and talk with our committee. And right now it is easier for us to invite them."

Mongkol also thinks Thailand carried out their recent compulsory licensing too transparently, and that other countries simply go ahead with compulsory licensing without announcing their intentions.

He is still waiting to hear whether Abbott Laboratories — the makers of two AIDS drugs Thailand has issued compulsory licences for — will agree to a proposal to sell seven drugs at a lower price for non-commercial use.

Link to full article in Science

Add your comment

This is your network: share your views on any of our articles by adding your comments.

You need to be signed in to post a comment or to email a consenting comment author. Please sign in or sign up.

All comments are subject to approval and we reserve the right to edit comments containing inappropriate/unsuitable language. SciDev.Net holds copyright for all material posted on the website. Please see terms of use for further details.

All SciDev.Net material is free to reproduce providing that the source and author are appropriately credited. For further details see Creative Commons.

Back to News
To the top